Vernalis plc

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Three milestones in Servier and Vernalis oncology drug discovery collaboration

Two research milestones and one clinical milestone, triggering a total payment of €2m to Vernalis
Research & Development

Servier and Vernalis announce three milestones in their oncology drug discovery collaboration

Two research milestones and one clinical milestone reached, triggering a total payment of €2 million to Vernalis
Research & Development

Vernalis and Servier enter drug discovery collaboration

Vernalis and Servier will enter into a new two-year oncology drug discovery collaboration on an undisclosed target
Regulatory

FDA accepts CCP-08 NDA for full review

PDUFA date of 4 August 2017
Research & Development

Sandford Sommer joins Vernalis as President & Chief Operating Officer

Prior to joining the UK firm Sommer spent 24 years at AstraZeneca
Research & Development

Pharmaceutical industry rewarded in Queen\'s Awards for Enterprise 2014

Four companies honoured for International Trade and two for Innovation
Subscribe now